BENLYSTA patient story

Dr. Grace Wright, Rheumatologist

Paid consultant to GSK at the time of filming.

video transcript

 

DR. WRIGHT: I’m Doctor Grace Wright, a Rheumatologist in New York City

ON-SCREEN TEXT: Dr. Grace Wright, Rheumatologist
Paid consultant to GSK at the time of filming.

ON-SCREEN TEXT: “Meet a patient on BENLYSTA”
Stay tuned for Important Product Information

DR. WRIGHT: So I think back to when BENLYSTA was first approved and another patient that I placed on therapy. This was a young woman who came to me in her 40s, she had a young daughter at home, she was an executive, long days at work, and now she has lupus.

ON-SCREEN TEXT: Patient experience may not be representative of all BENLYSTA patients.

DR. WRIGHT: She’s got mouth ulcers, she’s got joint pain and stiffness, and her elbow in particular was a problem, because she sat at these meetings, and her elbow really was distracting. And I remember her coming in saying – we are doing all of the usual things, the antimalarials, the corticosteroids, all of these other therapies – and she just wasn’t well enough for her.

ON-SCREEN TEXT: “She just wasn’t well enough for her”

DR. WRIGHT: And so we talked about going on this infusion therapy at the time, that’s what we had offered, and so this was BENLYSTA which we administered in the office and she chose to try this, and what she noticed was her disease activity improved, and so she was able to function better, her joint pains improved, the ulcers that she had improved,...

ON-SCREEN TEXT: “Her disease activity improved”
Patient experience may not be representative of all BENLYSTA patients.

DR. WRIGHT: ... and so for her this was the right choice. And this was something that she was very thankful that we had an opportunity to offer her at that time.

ON-SCREEN TEXT: “For her, this was the right choice”

ON-SCREEN TEXT: BENLYSTAHCP.com

DR. WRIGHT: Thank you for watching. Visit the BENLYSTA website for more information.

ON-SCREEN BUTTON: Visit the website

VOICEOVER:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active central nervous system lupus. Reported: serious & sometimes fatal infections; progressive multifocal leukoencephalopathy; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

ON-SCREEN TEXT:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5+ with active SLE or active lupus nephritis. Not for use in severe active CNS lupus. Reported: serious & sometimes fatal infections; PML; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

ON-SCREEN TEXT:
BENLYSTA
(belimumab)
Intravenous Use 120 mg/vial
Subcutaneous Use 200 mg/mL

GSK Logo

Trademarks are owned by or licensed to the GSK group of companies. 
©2022 GSK or licensor. BELVID220049 August 2022 Produced in USA.

You may also like

Why BENLYSTA?

Dr. Alvin Wells, Rheumatologist

BENLYSTA patient story

Dr. Grace Wright, Rheumatologist

Paid consultants to GSK at the time of filming.

Icon: Computer

Join us for a live webinar

Learn more